meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
AKT inhibitor
capivasertib based treatment
capivasertib
capivasertib plus paclitaxel
ipatasertib based treatment
ipatasertib plus paclitaxel
chemotherapy
platinum-based chemotherapy
platinum derivate
platinum association
paclitaxel plus carboplatin
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus nab-paclitaxel
atezolizumab plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
poly ADP-ribose polymerase (PARP) inhibitor
veliparib plus paclitaxel plus carboplatin
no study with result for this clinical condition